Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > Conference Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2182)
•••
Comment by lscfaon Oct 22, 2015 9:27pm
142 Views
Post# 24219024

RE:Conference Call

RE:Conference Call
lscfa wrote:
 
 
the $30 million EBITDA guidance for 2015 is a conservative estimate
 
have engaged some external business development talent to pursue new drug acquisitions
 
the 10 products MSL is looking at acquiring vary in size
 
in most of the 28 European countries MSL sells only 1 product so there is an opportunity to get synergies with additional product introductions
 
smaller acquisitions can be done without raising any additional financing
 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities